Myeloma patients face elevated risk of preventable infections

Swedish researchers tracking 8,672 myeloma patients found they suffer disproportionately high rates of vaccine-preventable infections like respiratory syncytial virus. The finding suggests cancer treatment protocols may require rethinking vaccination strategies, with implications for pharmaceutical companies developing vaccines and hospitals managing immunocompromised patient populations.

Originaltitel: Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma: A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry